Tekla World Healthcare Fund THW
We take great care to ensure that the data presented and summarized in this overview for Tekla World Healthcare Fund is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding THW
View all-
Morgan Stanley New York, NY927KShares$10.7 Million0.0% of portfolio
-
International Assets Investment Management, LLC Orlando, FL683KShares$7.88 Million0.14% of portfolio
-
Royal Bank Of Canada Toronto, A6460KShares$5.31 Million0.0% of portfolio
-
Core Cap Advisors, LLC Southfield, MI302KShares$3.49 Million0.19% of portfolio
-
Lpl Financial LLC Fort Mill, SC299KShares$3.45 Million0.0% of portfolio
-
Commonwealth Equity Services, LLC231KShares$2.66 Million0.0% of portfolio
-
Steward Partners Investment Advisory, LLC192KShares$2.22 Million0.02% of portfolio
-
Ubs Group Ag159KShares$1.84 Million0.0% of portfolio
-
Raymond James & Associates St Petersburg, FL148KShares$1.71 Million0.0% of portfolio
-
Cambridge Investment Research Advisors, Inc.96.3KShares$1.11 Million0.0% of portfolio
Latest Institutional Activity in THW
Top Purchases
Top Sells
About THW
Tekla World Healthcare Fund is a closed-ended balanced mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity and fixed income markets across the globe. It seeks to invest in stocks of companies operating in the healthcare sector. For its fixed income portion, the fund primarily invests in corporate debt securities. Tekla World Healthcare Fund was formed on June 26, 2015 and is domiciled in the United States.
Insider Transactions at THW
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 14
2024
|
Bill Maher Director |
BUY
Open market or private purchase
|
Direct |
1,000
+50.0%
|
$13,000
$13.03 P/Share
|
|
Jul 16
2024
|
Rose Di Martino Director |
BUY
Open market or private purchase
|
Direct |
1,000
+50.0%
|
$13,000
$13.31 P/Share
|
|
Apr 09
2024
|
Kathleen Goetz Director |
BUY
Open market or private purchase
|
Direct |
200
+16.43%
|
$2,400
$12.53 P/Share
|
|
Jan 02
2024
|
Todd Reit Director |
BUY
Open market or private purchase
|
Direct |
1,000
+50.0%
|
$11,000
$11.94 P/Share
|
|
Mar 23
2022
|
Kathleen Goetz Director |
BUY
Open market or private purchase
|
Direct |
103
+11.2%
|
$1,442
$14.52 P/Share
|
|
Jan 26
2022
|
Kathleen Goetz Director |
BUY
Open market or private purchase
|
Direct |
714
+50.0%
|
$9,996
$14.6 P/Share
|
|
Apr 06
2021
|
Thomas M Kent Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
600
+20.0%
|
$8,400
$14.26 P/Share
|
|
Apr 06
2021
|
Daniel R Omstead President |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
6,442
+17.31%
|
$90,188
$14.26 P/Share
|
|
Apr 06
2021
|
William S Reardon Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
486
+19.98%
|
$6,804
$14.26 P/Share
|
|
Apr 06
2021
|
Lucinda H Stebbins Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
250
+20.0%
|
$3,500
$14.26 P/Share
|
|
Apr 06
2021
|
Jeffrey Allen Bailey Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
245
+20.0%
|
$3,430
$14.26 P/Share
|
|
Feb 25
2021
|
William S Reardon Director |
BUY
Open market or private purchase
|
Direct |
1,460
+50.0%
|
$24,820
$17.14 P/Share
|
|
Feb 19
2021
|
Lucinda H Stebbins Director |
BUY
Open market or private purchase
|
Direct |
750
+50.0%
|
$12,000
$16.8 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 3.2K shares |
|---|